Drug Shortage Report for CAELYX
| Report ID | 274720 |
| Drug Identification Number | 02238389 |
| Brand name | CAELYX |
| Common or Proper name | CAELYX (Liposomal Doxorubicin), 20mg / 10mL vial |
| Company Name | BAXTER CORPORATION |
| Market Status | MARKETED |
| Active Ingredient(s) | DOXORUBICIN HYDROCHLORIDE |
| Strength(s) | 2MG |
| Dosage form(s) | SUSPENSION |
| Route of administration | INTRAVENOUS INTRAVENOUS |
| Packaging size | 20mg / 10mL vial |
| ATC code | L01DB |
| ATC description | CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | 2026-04-25 |
| Actual start date | |
| Estimated end date | Unknown |
| Actual end date | |
| Shortage status | Anticipated shortage |
| Updated date | 2025-12-19 |
| Company comments | Delay in production and shipment of new lot |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 7125 MISSISSAUGA ROAD MISSISSAUGA, ONTARIO CANADA L5N 0C2 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v3 | 2025-12-19 | French | Compare |
| v2 | 2025-12-19 | English | Compare |
| v1 | 2025-12-19 | English | Compare |
Showing 1 to 3 of 3